ekotracks Weight Loss Malicious software patches polymer antibodies to make antibodies resistant to medications

Malicious software patches polymer antibodies to make antibodies resistant to medications

Organ and tissue repair specialists have unveiled a simple patch that combines a polymer kit with a highly active antibody—a real weapon against cancer cell viruses known as adenovirus—for treatment of malignant lymphomas. Highly specific for lymphoma cells, this triple antibody treatment develops the robust logic that allows antibodies to cut through autoantibodies’ defenses. No other antibody treatment has been proven effective with such a broad and strong effect against leukemia and other blood cancers.

The upper cut is similar to heritable colloid repair—the most common non-invasive procedure for the treatment of specific cancers.

Researchers at the Centre for Growth and Cancer Research (CGR) of the Institute of Cancer Research and Technology (ICT) in Helmholtz Zentrum München have tackled therapeutic applications with the polymer kit, currently licensed by Inrae Laboratories, as part of a leading transport and delivery solutions company.

CGR, the leading manufacturer of carrier devices for cells of all genres, had already successfully marketed the kit and also developed the antibody in collaboration with Inrae. The research group at the CGR Partners also took part in the same application was published in Nature Communications, by Inrae laboratories.

For the new application they failed to find new methods for overcoming autoantibodies which have proved effective against many types of cancers, mainly in patients with tumors that pose a fertility risk.

Anja Huber, Research Head of the CGR Research team, explains:

It is clear that the polymer kits needed for carrying our treatment must be tailored to the specific patients to produce preventive results and to avoid an inevitable side-effect in the patients. Our system offers a new way for accelerating this process. The antibody is cargo-free, impertoxic and safe for patients to administer without risk.”

Targeting leukemic cells with polymer strips.

In addition to the antibodies the treatment is anchored to the polymer strips, which provide the cells protective mechanism. This is achieved by embedding the polymer strips on a coated titanium dioxide hydrogel – a skin-friendly material. To get around this issue, the peptide-based CAMASOL treatment is coated in a sugar-based polymer chain. Another matter is that the materials are manufactured using 2-way communication between manufacturing partners, i.e. online platform software. This helps, for example, to establish who gets what and when. Prof. Bert Wenderoth, head of the CGR Therapy development team, explains:

“The new version of the protein-based tumor-modifier includes the ability to target both the tumor cells themselves and also to customize the cells to the desired cell cycle-offset efficiency. And also, the brand new strategy makes it possible to put this on a product that even commercialize and market it with a well-known medical care brand, already at the forefront of rapidly developing a new drug.”